12 Months, page-23

Patent pending provides a certain layer of protection throughout US,AU, Asia and Europe in RAP's case. RAP also filed for additional patents in Feb and August 2017, for improved and improvement to the previous patent - respectively. Given these further patents are not available for us to view, can only guess it includes the extra features learnt from US trial which make the algo more "robust" - so competitors can't learn/copy from our mistakes.

Further - if a copy does appear and available will the consumer prefer the clinically proven product or the copy. Usually copy apps pose no issue and have a high uptake - I'm not sure if this will be the case for health related apps which actually have real issues if not diagnosed correctly.

Since Feb 2017 the Aus trials have been configured for CE Marka and TGA. CE mark is required throughout the European Union + a few other countries. Add in TGA and you have over 30 countries in which RAP has clinically proven tech.

In Aus I personally don't care or even know if FDA has approved any products I use or will use. So maybe in the jurisdiction you live in you only care about your own approval - so shouldn't be any revenue concerns.

However - we must acknowledge that FDA is perceived at least by the market - to be the only clinically valid seal of approval. It's a pity MSF had to suspend their association with RAP for the time being, but I understand. Maybe when we get CE and TGA they may at least look into it again.

To repeat what others have said let's go over one more time what will be different this US trials.
- Dr Currie - experience in clinical trials and was a lead investigator in one of these hospitals previously
- Algo ignoring the 30hz low frequency sounds which previously skewed results
- No treatment to patient prior to coughs (exclude asthma and croup as not ethical to do so) so when they cough it's actually when their sick
- Do not automatically collect first 5 coughs - this was previously built in to the app
- prompts on app screen to turn of tv etc
- Sound check - if the surrounding atmosphere
sound isn't suitable it won't let you record.
- RAP to have access to cough samples only a few days after the cough recording - can immediately discard inappropriate coughs (this could potentially delay the trial???)
- More on ground presence of RAP during trial for ongoing training
- Reduce subjectivity of clinical diagnosis. This is a big one and not sure why it's not discussed much here. apply a more tightened set of clinical case definitions - so everyone is on the same page that these certain signs and symptoms = this disease.

Happy to be corrected on any of the above.
IMO and DYOR.